Hepatitis C pharmacogenetics: state of the art in 2010
- PMID: 21254181
- DOI: 10.1002/hep.24052
Hepatitis C pharmacogenetics: state of the art in 2010
Abstract
In 2009, a correlated set of polymorphisms in the region of the interleukin-28B (IL28B) gene were associated with clearance of genotype 1 hepatitis C virus (HCV) in patients treated with pegylated interferon-alfa and ribavirin. The same polymorphisms were subsequently associated with spontaneous clearance of HCV in untreated patients. The link between IL28B genotype and HCV clearance may impact decisions regarding initiation of current therapy, the design and interpretation of clinical studies, the economics of treatment, and the process of regulatory approval for new anti-HCV therapeutic agents.
Copyright © 2010 American Association for the Study of Liver Diseases.
Comment in
-
Genetic background of hepatocyte cell lines: are in vitro hepatitis C virus research data reliable?Hepatology. 2011 Aug;54(2):748. doi: 10.1002/hep.24278. Hepatology. 2011. PMID: 21384407 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical